Skip to content
Business Company News, Oil Mining Resources

C29 Metals Expands Kazakhstan Multi-Mineral Project with New Exploration Approval

Jane Morgan Management < 1 mins read

Perth, Australia – 19 June 2025 – ASX-listed C29 Metals Limited (ASX: C29), an emerging multi-mineral exploration company, is pleased to announce that its wholly owned Kazakhstan subsidiary has secured Category 4 exploration approval for its newly granted eastern tenement (Licence #3233-EL), expanding the Company's highly prospective exploration footprint in southern Kazakhstan by approximately 116km².

The tenement, granted in March 2025, lies contiguous to the Company’s southern tenement and enables the commencement of airborne geophysical surveys, field mapping, and soil sampling across the area. C29 is also progressing the Category 2 drilling permits for both its southern (#2786-EL) and northern (#2826-EL) tenements.

The Company recently completed successful community consultation sessions in the Zhambyl and Almaty regions, with strong local support reaffirming its commitment to transparent and cooperative development.

C29 Metals Managing Director, Mr Shannon Green, commented: 

“It is very pleasing to receive the Category 4 approval, which further demonstrates the Company’s ability to achieve its stated strategy, of growing & exploring its highly prospective multi mineral Project in southern Kazakhstan. The permit approval & the success of our community consultation days is a continued demonstration of the support that the Company is experiencing on the ground in Kazakhstan”

With exploration planning already underway—including airborne geophysics across multiple tenements—C29 Metals continues to solidify its position in a highly prospective mineral district.

 


Contact details:

For further information, please contact:

Jane Morgan
Investor & Media Relations
[email protected]

Media

More from this category

  • Business Company News, Medical Health Aged Care
  • 08/07/2025
  • 11:08
Nova Eye Medical (ASX:EYE)

Nova Eye Medical Delivers Record Revenues for FY25

HIGHLIGHTS Record revenues of A$28.8m for the year ended 30 June 2025 and in line with guidance Six consecutive half-years of growth in the USA with H2FY25 US sales up 25% onpcp Q4FY25 sales of A$8.4m the highest on record Nova Eye Medical Limited (ASX: EYE) (Nova Eye or the Company) is pleased to report a record sales result for FY25. Group revenue for FY25 reached A$28.8 million (US$18.4 million), up 21% (in constant currency) from FY24. Key drivers include: US sales of US$14.2 million, up 25% withiTrack™ Advance delivering six consecutive half-years of revenue growth. H2FY25 sales A$15.7 million…

  • Business Company News, Manufacturing
  • 08/07/2025
  • 10:38
Jane Morgan Management

Amaero Unlocks Velo3D Supply Agreement with Powder Certification from Auburn’s NCAME

Sydney, Australia – Amaero Ltd (ASX:3DA, OTC: AMROF) (“Amaero” or “the Company”) has entered into a strategic collaboration with Auburn University’s National Center for Additive Manufacturing Excellence (NCAME) to accelerate development and testing of its proprietary C103 and Ti64 alloy powders. The collaboration has already delivered key milestones. NCAME has verified that Amaero’s powders meet key aerospace and additive manufacturing standards, including ASTM F3635 for C103 and AMS7015/ASTM F3001 for Ti64. As a result, Amaero has met the powder qualification condition set by advanced 3D printing company Velo3D - clearing the way for initial commercial orders. Velo3D has now placed…

  • Contains:
  • Biotechnology, Business Company News
  • 08/07/2025
  • 10:02
Jane Morgan Management

BlinkLab Expands U.S. Clinical Trial Network – University of Nebraska Medical Center Engaged as Second Site in Main Phase of FDA 510(k) Study

BlinkLab Limited (ASX:BB1) (“BlinkLab” or “the Company”) is pleased to announce the expansion of its U.S. clinical trial network with the University of Nebraska Medical Center (UNMC) engaged as the second site in the main phase of its FDA 510(k) study for BlinkLab Dx 1 – its smartphone-based diagnostic tool for early autism detection. Highlights Second U.S. Site: University of Nebraska Medical Center (UNMC) selected as second site for BlinkLab’s pivotal FDA 510(k) autism diagnostic trial. Pilot Phase Near Completion: BlinkLab’s 100-participant pilot study has been progressing towards completion, with results expected this quarter. Main Study Scaling: An additional 750–900…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.